Riskpilot← Back to searchSign inGet full accessRABMED AS
ASActiveOrg 916817606Sagveien 23C, 0459 OsloAnnen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk · NACE 72190Est. 20160 employees
Revenue 2023
NOK 0
EBITDA margin
—
-24411% vs 2022
Equity ratio
-1746.0%
Financial strength
Net profit 2023
NOK -4,9M
-21399% vs 2022
| Revenue | NOK 0 | — |
| EBITDA | NOK -4,9M | -24411% |
| Net profit | NOK -4,9M | -21399% |
| Total assets | NOK 218K | -96% |
| Equity | NOK -3,8M | -453% |
| Employees | 0 | — |
Legal name
RABMED AS
Org number
916817606
Legal form
Aksjeselskap
NACE code
72190 · Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk
Founded
29. februar 2016
Share capital
NOK 85 356
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling og kommersialisering av internasjonalt banebrytende medisintekniske løsninger.
Address
Sagveien 23C, 0459 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50 | 0 | 325 | 325 | 25 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −0 | −20 | 194 | 262 | −44 | −55 | −20 | −4 874 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −0 | −20 | 194 | 262 | −44 | −55 | −20 | −4 874 |
| Net financials | 0 | −16 | −152 | −167 | −159 | −153 | −3 | −0 |
| Profit before tax | −0 | −35 | 42 | 95 | −203 | −208 | −23 | −4 874 |
| Tax | −0 | −0 | 32 | 21 | −21 | −0 | −0 | −0 |
| Net profit | −0 | −35 | 10 | 74 | −182 | −208 | −23 | −4 874 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 25 | 1 544 | 2 981 | 5 134 | 5 170 | 5 116 | 5 135 | 218 |
| Equity | 24 | 303 | 816 | 1 487 | 1 305 | 1 098 | 1 075 | −3 799 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 1 241 | 2 165 | 3 646 | 3 864 | 4 018 | 4 060 | 4 017 |
| Total debt | 1 | 1 241 | 2 165 | 3 646 | 3 864 | 4 018 | 4 060 | 4 017 |
EBITDA margin
-487386400.0%
This company
15.8%
Market median
-3084724151% vs market
20162023
Equity ratio
-1746.0%
This company
38.2%
Market median
-4671% vs market
20162023
Return on equity
-487409400.0%
This company
18.4%
Market median
-2648964230% vs market
20162023
Net profit margin
-487409400.0%
This company
8.1%
Market median
-6017400100% vs market
20162023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162023
Debt / equity
1.06×
This company
0.62×
Market median
-71% vs market
20162023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-02-04 – 2016-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
K8 Invest As | Company | 37.9% | 37.9% | 2024 |
| Individual | 5.1% | 5.1% | 2024 | |
| Individual | 3.5% | 3.5% | 2024 | |
| Individual | 3.0% | 3.0% | 2024 | |
Kasper As | Company | 2.8% | 2.8% | 2024 |
Sva Eie As | Company | 2.4% | 2.4% | 2024 |
Beauville As | Company | 1.6% | 1.6% | 2024 |
| Individual | 1.6% | 1.6% | 2024 | |
Cleve Broch As | Company | 1.3% | 1.3% | 2024 |
Brødrene London As | Company | 1.3% | 1.3% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RABMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Vollen | Board of Directors | 0 companies |
| Marius Andresen | Chairman | 0 companies |